We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+62.1%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$4.18B
AUM Growth
+$1.19B
Cap. Flow
+$143M
Cap. Flow %
3.41%
Top 10 Hldgs %
48.69%
Holding
88
New
15
Increased
28
Reduced
14
Closed
24

Top Buys

1
BIIB icon
Biogen
BIIB
+$127M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$72.2M
3
BSX icon
Boston Scientific
BSX
+$68.3M
4
APRE icon
Aprea Therapeutics
APRE
+$62.5M
5
UNH icon
UnitedHealth
UNH
+$52.9M

Top Sells

1
ALDR
Alder Biopharmaceuticals
ALDR
+$155M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$114M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$87.2M
4
CELG
Celgene Corp
CELG
+$55.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$49.6M

Sector Composition

1 Healthcare 98.47%
2 Industrials 0.33%
3 Technology 0%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAH
26
DELISTED
PRA Health Sciences, Inc.
PRAH
$50M 1.2%
449,800
+54,400
+14% +$5.6M
AXNX
27
DELISTED
Axonics, Inc. Common Stock
AXNX
$42.5M 1.02%
1,532,000
+722,300
+89% +$17.2M
HCA icon
28
HCA Healthcare
HCA
$85.6B
$42.2M 1.01%
285,200
+49,700
+21% +$6.67M
PTCT icon
29
PTC Therapeutics
PTCT
$6.51B
$41.3M 0.99%
+859,526
New +$36.5M
EIDX
30
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$40.2M 0.96%
701,178
-221,825
-24% -$11M
REPL icon
31
Replimune Group
REPL
$799M
$39.7M 0.95%
2,766,407
+552,990
+25% +$7.97M
SRRK icon
32
Scholar Rock
SRRK
$6.2B
$38.8M 0.93%
2,940,889
+83,500
+3% +$801K
BOLD
33
DELISTED
Audentes Therapeutics, Inc
BOLD
$38.2M 0.91%
639,095
-2,323,560
-78% -$87.2M
GH icon
34
Guardant Health
GH
$20.6B
$30.5M 0.73%
+389,700
New +$28.1M
ELV icon
35
Elevance Health
ELV
$80.9B
$30.4M 0.73%
+100,800
New +$27.7M
AMED
36
DELISTED
Amedisys
AMED
$30.2M 0.72%
181,065
+178,745
+7,705% +$26.6M
CI icon
37
Cigna
CI
$75.1B
$30.2M 0.72%
+147,500
New +$27M
ARDX icon
38
Ardelyx
ARDX
$1.27B
$30M 0.72%
+4,000,000
New +$24.3M
STOK icon
39
Stoke Therapeutics
STOK
$1.81B
$28.9M 0.69%
1,020,778
+3,300
+0.3% +$83K
GRTS
40
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$28M 0.67%
3,116,594
+12,100
+0.4% +$101K
WVE icon
41
Wave Life Sciences
WVE
$1.09B
$26.7M 0.64%
3,326,493
+148,733
+5% +$3.65M
AKRO
42
DELISTED
Akero Therapeutics
AKRO
$25.8M 0.62%
1,164,002
-400
-0% -$8.28K
TCRR
43
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$25.7M 0.61%
1,799,188
+8,900
+0.5% +$138K
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$25.6M 0.61%
790,071
+16,500
+2% +$511K
SWAV
45
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$24.9M 0.6%
+567,900
New +$21M
NGNE icon
46
Neurogene
NGNE
$728M
$23.7M 0.57%
+96,042
New +$9.57M
HOOK
47
DELISTED
HOOKIPA Pharma
HOOK
$23.1M 0.55%
189,252
-520
-0.3% -$44.2K
XERS icon
48
Xeris Biopharma Holdings
XERS
$1.5B
$21.2M 0.51%
3,000,641
– –
GMAB icon
49
Genmab
GMAB
$17.8B
$20.9M 0.5%
936,700
-311,900
-25% -$6.81M
CABA icon
50
Cabaletta Bio
CABA
$435M
$20M 0.48%
+1,431,696
New +$17M
1
2
3 4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q4 2019 Portfolio in Review

As of Q4 2019, Redmile Group held 88 positions worth $4.18B, up 40% from $2.99B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group deployed $143M of net new capital in Q4 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Biogen: 457,500 shares worth $136M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Audentes Therapeutics, Inc, an estimated $87.2M trimmed.

  • Redmile Group's largest Q4 2019 buy was Biogen: 457,500 shares worth $136M.
  • Redmile Group added most to Principia Biopharma Inc. Common Stock in Q4 2019, an estimated $72.2M increase.
  • Redmile Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $87.2M.
  • Redmile Group fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $155M.
  • Redmile Group's ten largest holdings make up 49% of its $4.18B portfolio in Q4 2019.
  • Redmile Group opened 15 new positions and closed 24 in Q4 2019.
  • Redmile Group's portfolio value rose 40% quarter-over-quarter to $4.18B.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.